Flu-Related Hospitalizations in Children

An estimated 20,000 children are hospitalized each year with influenza-related illnesses. Children with certain chronic conditions are at higher risk for serious influenza (flu) complications, and recommendations for annual flu vaccines have been targeted at these children. Over the past four years, public health officials have expanded their recommendations about which children should be immunized against the flu. This Issue Brief summarizes clinical outcomes and costs from the largest study to date of children hospitalized with the flu. These findings should help inform clinicians and policymakers in prioritizing their efforts to implement the new recommendations

Epidemiology and potential preventative measures for viral infections in children with malignancy and those undergoing hematopoietic cell transplantation.

In pediatric patients with malignancy and those receiving hematopoietic stem cell transplants, bacterial and fungal infections have been the focus of fever and neutropenia episodes for decades. However, improved diagnostic capabilities have revealed viral pathogens as a significant cause of morbidity and mortality. Because of limited effective antiviral therapies, prevention of viral infections is paramount. Pre-exposure and post-exposure prophylaxis and antiviral suppressive therapeutic approaches are reviewed. Additionally, infection control practices specific to this patient population are discussed. A comprehensive approach utilizing each of these can be effective at reducing the negative impact of viral infections

Effect of clinical pathways on antibiotic prescriptions in an emergency department: Italian pediatric antimicrobial stewardship starts here

n/

A novel heuristic algorithm for the modeling and risk assessment of the covid-19 pandemic phenomenon

The modeling and risk assessment of a pandemic phenomenon such as COVID-19 is an important and complicated issue in epidemiology, and such an attempt is of great interest for public health decision-making. To this end, in the present study, based on a recent heuristic algorithm proposed by the authors, the time evolution of COVID-19 is investigated for six different countries/states, namely New York, California, USA, Iran, Sweden and UK. The number of COVID-19-related deaths is used to develop the proposed heuristic model as it is believed that the predicted number of daily deaths in each country/state includes information about the quality of the health system in each area, the age distribution of population, geographical and environmental factors as well as other conditions. Based on derived predicted epidemic curves, a new 3D-epidemic surface is proposed to assess the epidemic phenomenon at any time of its evolution. This research highlights the potential of the proposed model as a tool which can assist in the risk assessment of the COVID-19. Mapping its development through 3D-epidemic surface can assist in revealing its dynamic nature as well as differences and similarities among different districts

VACCELERATE Site Network: Real-time definition of clinical study capacity in Europe

Background: The inconsistent European vaccine trial landscape rendered the continent of limited interest for vaccine developers. The VACCELERATE consortium created a network of capable clinical trial sites throughout Europe. VACCELERATE identifies and provides access to state-of-the-art vaccine trial sites to accelerate clinical development of vaccines. Methods: Login details for the VACCELERATE Site Network (vaccelerate.eu/site-network/) questionnaire can be obtained after sending an email to. Interested sites provide basic information, such as contact details, affiliation with infectious disease networks, main area of expertise, previous vaccine trial experience, site infrastructure and preferred vaccine trial settings. In addition, sites can recommend other clinical researchers for registration in the network. If directly requested by a sponsor or sponsor representative, the VACCELERATE Site Network pre-selects vaccine trial sites and shares basic study characteristics provided by the sponsor. Interested sites provide feedback with short surveys and feasibility questionnaires developed by VACCELERATE and are connected with the sponsor to initiate the site selection process. Results: As of April 2023, 481 sites from 39 European countries have registered in the VACCELERATE Site Network. Of these, 137 (28.5 %) sites have previous experience conducting phase I trials, 259 (53.8 %) with phase II, 340 (70.7 %) with phase III, and 205 (42.6 %) with phase IV trials, respectively. Infectious diseases were reported as main area of expertise by 274 sites (57.0 %), followed by any kind of immunosuppression by 141 (29.3 %) sites. Numbers are super additive as sites may report clinical trial experience in several indications. Two hundred and thirty-one (47.0 %) sites have the expertise and capacity to enrol paediatric populations and 391 (79.6 %) adult populations. Since its launch in October 2020, the VACCELERATE Site Network has been used 21 times for academic and industry trials, mostly interventional studies, focusing on different pathogens such as fungi, monkeypox virus, Orthomyxoviridae/influenza viruses, SARS-CoV-2, or Streptococcus pneumoniae/pneumococcus. Conclusions: The VACCELERATE Site Network enables a constantly updated Europe-wide mapping of experienced clinical sites interested in executing vaccine trials. The network is already in use as a rapid-turnaround single contact point for the identification of vaccine trials sites in Europe.The VACCELERATE Site Network has received funding from the European Union’s Horizon 2020 research and innovation pro gramme (grant agreement No 101037867) and the German Federal Ministry of Education and Research (Bundesministerium für Bil dung und Forschung [BMBF]) (grant agreement No BMBF01KX2040).S